Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) is a biopharmaceutical company specializing in the development and commercialization of treatments for gastrointestinal (GI) diseases. Best known for its leading drug, LINZESS®, which treats irritable bowel syndrome and chronic constipation, the company focuses on advancing innovative GI therapies. Through continued research and strategic partnerships, Ironwood remains dedicated to improving patient outcomes in gastroenterology.
最新股票文章
為何麥可·貝瑞（Michael Burry）剛剛清倉所有股票
麥可·貝瑞剛剛拋售了超過7,000萬美元的股票，清空了他的整個投資組合，只保留一支股票，並對這家公司加碼，而其他投資人則紛紛出逃。
18:37, 22 7月 2025
評級和評論
評級和評論
